CRTX Financial Facts

Weighted-average common shares, diluted: 31.5M
Research and development: 594K
See Full Income Statement

Total assets: 390.07M
Income tax receivable: 0
See Full Balance Sheet

Cornerstone Therapeutics Inc. (CRTX) Earnings

  |   Expand Research on CRTX
Next EPS Date N/A EPS Growth Rate +142.1% *Last Qtr.
Average EPS % Beat Rate -68.0% Revenue Growth Rate +43.2% *Last Qtr.
Average % Move 1-Wk after EPS +5.9% Normal Earnings Time Before Open
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
11/7/13 Q313 $0.46$0.27 +$0.19$53.7M$42M N/A Details
8/6/13 Q213 $0.19$0.12 +$0.07$40.4M$35.79M N/A Details
3/14/13 Q412 -$0.26$0.10 -$0.36$34.93M$36.04M N/A Details
11/8/12 Q312 $0.19$0.32 -$0.13$37.5M$32M N/A Details
8/9/12 Q212 -$0.17-$0.02 -$0.15$21.47M$18.84M N/A Details
5/15/12 Q112 $0.05$0.10 -$0.05$22.2M$20M N/A Details
3/8/12 Q411 -$0.06$0.09 -$0.15$18.21M$24.58M N/A Details
11/3/11 Q311 $0.13$0.14 -$0.01$25.18M$28.39M N/A Details